Cardiff Oncology CRDF
NASDAQ CRDF
$0.91 -0.02 (-2.15%)
At close: Oct 23, 2026 · 4:00 PM EDT

Cardiff Oncology (CRDF) Gains from Sales and Divestitures (2014 - 2022)

Updated

Cardiff Oncology (CRDF) posted Gains from Sales and Divestitures of -$1,000 for Q4 2022.

Analysis

Cardiff Oncology (CRDF) Gains from Sales and Divestitures (2014 - 2022) Analysis & Trends

Since Q1 2014, Cardiff Oncology has reported Gains from Sales and Divestitures for 11 quarters.

  • In prior years, Cardiff Oncology's Gains from Sales and Divestitures was -$1,000 in FY2021 and -$362,949 in FY2018.
  • Quarterly Gains from Sales and Divestitures has run from a low of -$165,459 in Q4 2018 to a high of $609.00 in Q3 2018 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Cardiff Oncology 62.34 Mn 27.84 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -1,000.00
Mar 31, 2021 -1,000.00
Dec 31, 2018 -165,459.00
Sep 30, 2018 609.00
Dec 31, 2017 -426,852.00
Sep 30, 2017 -102.00
Dec 31, 2016 -577,314.00
Sep 30, 2015 -8,130.00
Mar 31, 2015 3,568.00
Sep 30, 2014 -19,255.00
Mar 31, 2014 44,101.00
API Access

Cardiff Oncology Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CRDF&period=max&api_key=YOUR_API_KEY